Recognized standard
E2524-22
FDA recognition 18-24 · ASTM · Nanotechnology
Key facts
| Recognition number | 18-24 |
|---|---|
| Designation | E2524-22 |
| Title | Standard Test Method for Analysis of Hemolytic Properties of Nanoparticles |
| Standards developer | ASTM International |
| Specialty area | Nanotechnology |
| Date of entry | Dec 18, 2023 |
| Scope (excerpt) | 1.1 This test method covers assessing the effect of nanoparticulate materials on the integrity of red blood cells. 1.2 This test method uses diluted whole blood incubated with nanoparticulate material and the hemoglobin released from damaged red blood cells is determined. 1.3 This test method is… |
At a glance
- None Product codes
- 1–9 FDA guidance documents
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA-recognized consensus standards
The FDA recognizes voluntary consensus standards that manufacturers can cite in premarket submissions to show conformity with specific requirements.
Source: U.S. Food and Drug Administration (FDA), Recognized Consensus Standards database · Source date: